
|Articles|August 12, 2014
- Gastrointestinal Cancers (Issue 2)
- Volume 2
- Issue 1
Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC
Author(s)Paulo Marcelo Hoff, MD, PhD, FACP
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Advertisement
Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).
Learn about adverse events associated with regorafenib for mCRC > >
Articles in this issue
over 11 years ago
An Analysis of Bevacizumab or Cetuximab for CRCover 11 years ago
The Importance of Testing for BRAF Status in CRC Patientsover 11 years ago
Proactive Management of Regorafenib-Associated AEsover 11 years ago
Survival Benefit Confirmed With Palliative Resection in mCRCAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
5



















